|
健保碼及健保價 |
|
See related Vincristine-Teva inj[敏克瘤 注射劑] information |
|
|
|
製造商 |
Pharmachemie |
|
代理/經銷商 |
Centapharm |
|
成份 |
Vincristine sulfate |
|
適應症 |
Acute leukemia. |
|
用量 |
By IV administration. Adult 1.4 mg/m2, up to a max weekly dose of 2 mg/m2. Children > 10 kg 2 mg/m2/week, ≤ 10 kg Initially 0.05 mg/kg/week. |
|
美國食品藥物管理局之懷孕等級 |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
禁忌 |
Demyelinating form of Charcot-Marie-Tooth syndrome. Patients receiving radiation therapy. |
|
注意事項 |
Routine prophylactic laxative needed to ensure regular bowel movement. Regular ophth examination. Preexisting pulmonary dysfunction or neuromuscular disease. Avoid in pregnancy, lactation. |
|
不良反應 |
Alopecia, neurotoxicity. Leucopenia, neuritis. Hypersensitivity reactions, GI disturbances, dysuria, difficulty in micturition, urinary retention. HTN, hypotension. Acute dyspnea, svere bronchospasm. Bone marrow depression, fever, headache.
View ADR Monitoring Website[參閱藥物不良反應監測表格] |
|
交互作用 |
Itraconazole, phenytoin, asparginase, isoniazid & other neurotoxic drugs. Anti-gout, other myelosuppresive drugs. Mitomycin C, digoxin, vaccines.
View more drug interactions with Vincristine-Teva[敏克瘤] |
|
本商品之市售規格 |
|
劑型 |
包裝 |
圖片 |
|
Vincristine-Teva 注射劑 |
|
Vincristine-Teva 1 mg/1 mL x 1 mL |
|
Vincristine-Teva 1 mg/1 mL x 2 mL |
|
Vincristine-Teva 1 mg/1 mL x 5 mL |
|
|
|
Manufacturer: |
Pharmachemie |
|
Distributor: |
Centapharm |
|
|
|
|
|
